Showing 1 - 5 results of 5 for search 'Fenghuan Sun', query time: 0.04s Refine Results
  1. 1
    Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer

    Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer by Jian Chen, Yun Tan, Fenghuan Sun, Likun Hou, Chi Zhang, Tao Ge, Huansha Yu, Chunxiao Wu, Yuming Zhu, Liang Duan, Liang Wu, Nan Song, Liping Zhang, Wei Zhang, Di Wang, Chang Chen, Chunyan Wu, Gening Jiang, Peng Zhang

    Published 2020-06-01
    Get full text
    Article
  2. 2
    Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing

    Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing by Junjie Hu, Lele Zhang, Haoran Xia, Yilv Yan, Xinsheng Zhu, Fenghuan Sun, Liangdong Sun, Shuangyi Li, Dianke Li, Jin Wang, Ya Han, Jing Zhang, Dongliang Bian, Huansha Yu, Yan Chen, Pengyu Fan, Qiang Ma, Gening Jiang, Chenfei Wang, Peng Zhang

    Published 2023-03-01
    Get full text
    Article
  3. 3
    Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study

    Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study by Dongliang Bian, Liangdong Sun, Junjie Hu, Liang Duan, Haoran Xia, Xinsheng Zhu, Fenghuan Sun, Lele Zhang, Huansha Yu, Yicheng Xiong, Zhida Huang, Deping Zhao, Nan Song, Jie Yang, Xiao Bao, Wei Wu, Jie Huang, Wenxin He, Yuming Zhu, Gening Jiang, Peng Zhang

    Published 2023-08-01
    Get full text
    Article
  4. 4
    Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial

    Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial by Xinsheng Zhu, Liangdong Sun, Nan Song, Wenxin He, Boxiong Xie, Junjie Hu, Jing Zhang, Jie Yang, Jie Dai, Dongliang Bian, Haoran Xia, Fenghuan Sun, Anwen Xiong, Jie Luo, Lele Zhang, Huansha Yu, Ming Liu, Hongcheng Liu, Haifeng Wang, Haiping Zhang, Chang Chen, Chunyan Wu, Liang Duan, Yuming Zhu, Peng Zhang, Gening Jiang

    Published 2022-12-01
    Get full text
    Article
  5. 5
    Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study

    Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicent... by Haoran Xia, Han Zhang, Zheng Ruan, Huibiao Zhang, Liangdong Sun, Hezhong Chen, Yongxin Zhou, Lele Zhang, Dongliang Bian, Xinsheng Zhu, Jing Zhang, Fenghuan Sun, Huansha Yu, Nan Song, Xiaogang Liu, Yuming Zhu, Haiping Zhang, Wenxin He, Jian Chen, Jie Yang, Guohan Chen, Shiliang Xie, Dongfang Tang, Xiaomiao Zhang, Liang Duan, Deping Zhao, Qinchuan Li, Peng Zhang, Gening Jiang

    Published 2024-06-01
    Get full text
    Article

Search Tools: